Corticotropin releasing factor receptor antagonists: potential future therapy in gastroenterology?
New corticotropin releasing factor (CRF) antagonists in irritable bowel disease (IBS) warrant testing, and CRF1 receptors may be a promising target for the treatment of IBS.
Taché
Y
Y
CURE/Digestive Diseases Research Center, Bldg 115, Room 117, VA Greater Los Angeles Health Care System, 1130 Wilshire Blvd, Los Angeles, CA 90073, USA. yTaché@ucla.edu
D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000503:physiopathology / Q000628:therapy*; D018019:Receptors, Corticotropin-Releasing Hormone / Q000037:antagonists & inhibitors* / Q000502:physiology
D005765:Gastrointestinal Agents; D018019:Receptors, Corticotropin-Releasing Hormone